Introduction
============

Although much of the developed world has some level of universal health coverage, many vital health services still burden patients with significant out-of-pocket costs. In ophthalmology, this is perhaps truest in the field of pediatric ophthalmology where specifically the cost of contact lenses and glasses for refractive errors is rarely covered by single payer universal health care programs yet frequently prescribed.[@b1-rmhp-11-025],[@b2-rmhp-11-025]

This issue is compounded by several problems that are unique to pediatric eye care and eye pathology. Firstly, pediatric ophthalmic interventions and amblyopia treatment very commonly require refractive error correction in the form of eyeglasses, contact lenses, or intraocular lens implants.[@b3-rmhp-11-025] Secondly, the corrective lens prescription required to correct a child's vision can gradually change between follow-up appointments often requiring the purchase of multiple lenses.[@b3-rmhp-11-025] Additionally, most families have no/limited insurance and therefore find it very difficult to afford new or updated prescription lenses.[@b4-rmhp-11-025] Thus, many children can receive delayed vision correction that they have been prescribed. Lastly and perhaps most importantly, allowing a child to persist with an uncorrected refractive error for a prolonged period of time can result in irreversible amblyopia and permanent decline in visual acuity.[@b5-rmhp-11-025] All these points can be a source of great frustration to the provider for pediatric eye care.

The vast majority of information currently available on the costs surrounding pediatric eye care is from a health care spending perspective[@b6-rmhp-11-025],[@b7-rmhp-11-025] and does not consider out-of-pocket expenses the families of young children are expected to afford. Glasses break very frequently with activities of these young children and need to be replaced as frequently. This overburdens families and many tend to wait several weeks or months before finances are arranged or insurance benefits kick in.[@b8-rmhp-11-025] We know refractive errors and amblyopia can run in families, and many times multiple children in the family are also involved in simultaneous pediatric ophthalmology care.

We conducted a systematic review to summarize the costs a family might incur because of their child's prescription for vision and amblyopia correction and the overburden from a Ministry of Health perspective. Additionally, incremental cost per incremental effectiveness due to poor vision is considered. For the systematic review, multiple bibliographic databases were searched.

Methods
=======

Search strategy and selection criteria
--------------------------------------

In this project, we adhered to the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[@b9-rmhp-11-025] Literature, including published and unpublished scientific work, was systematically reviewed, and the following bibliographic databases were searched from January 2000 to May 2017: MEDLINE (OVID and PubMed), EMBASE (OVID), BIOSIS Previews (Thomson-Reuters), CINAHL (EBSCO), Health Economic Evaluations Database (HEED), ISI Web of Science (Thomson-Reuters), and the Cochrane Library (Wiley). Database-specific subject headings and key words were employed in the search strategy. The searches were modified to accommodate the unique terminology and syntax of each database. Additionally, all synonyms were considered with the help of information specialist (KH). OVID AutoAlerts were set up to send monthly updates with any new literature.

Gray literature was identified by searching the conference abstracts of various meetings including the Canadian Ophthalmology Society meeting, American Association of Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology annual meeting, European Society of Ophthalmology, and the Association for Research in Vision and Ophthalmology annual meeting. The ProQuest Dissertations and Theses databases and the Canadian Health Research Collection (Ebrary) were also searched for relevant content. Google and other Internet search engines were used to search for additional web-based materials and information.

Inclusion criteria
------------------

Inclusion criteria were as follows: 1) publication in English language, 2) pediatric population between the age of 3 and 10 years, 3) publication dates from 2000 and onwards, and 4) journal articles, systematic reviews, meta-analysis, cost analysis, cost-utility analysis, cost-effectiveness analysis, multicenter studies, randomized controlled trials, non-randomized studies including cohort studies (retrospective, prospective), clinical trials, and comparatives studies. There was no limit set by geography or country where the study was carried out. [Figure 1](#f1-rmhp-11-025){ref-type="fig"} summarizes the PRISMA flow diagram for including studies for meta-analysis.

Screening
---------

In total, 302 records were retrieved from multiple databases and additional 48 records were identified through gray literature search. These records were imported to EPPI-Reviewer 4 gateway (by EPPI-Centre, Social Science Research Unit, the Institute of Education, University of London, UK) to remove duplicates. After removing duplicates, 286 records were included for the three-level screening process ([Figure S1](#SD1-rmhp-11-025){ref-type="supplementary-material"}). Level 1 screening involved reviewing titles, Level 2 screening reviewed abstracts, and Level 3 screening involved full-text reviews of each included study by two reviewers, independently (RW and EL). At each level, agreement for inclusion between the two reviewers was assessed by Cohen's kappa (κ) coefficient. Articles were included for the next level of screening if both the reviewers agreed. Differences between the reviewers were discussed and resolved by consensus. In cases where consensus was not achieved, a third reviewer (MMM) provided a decision. After screening, 48 records were assessed for eligibility. From these, a final total of 14 studies were found eligible for our quantitative analysis ([Table 1](#t1-rmhp-11-025){ref-type="table"}).

Data extraction
---------------

Data were extracted from the 14 eligible articles using a data extraction form. The first reviewer extracted data from the included studies, and a second reviewer resolved errors or mistakes if any by reviewing the extracted data. Data extracted included study objective, design, location, inclusion and exclusion criteria, data collection technique, data collection period, total patients enrolled in and completed the study, refusal to consent, number of females, patient demographic characteristics, follow-up, diagnosis, cost of prescribed modality for vision correction, secondary cost to vision correction, visual outcome, and compliance.

For missing data, various pieces of available information (such as the range, *p*-value, and confidence interval) were utilized and converted to the common effect measure (treatment effect) -- SD. Further, corresponding authors were also contacted for additional information. Using a Downs and Black checklist,[@b10-rmhp-11-025] each included article was independently appraised by the two reviewers for quality.

Our main findings of the systematic review have been summarized in a tabular form. [Table 1](#t1-rmhp-11-025){ref-type="table"} lists the characteristics of the extracted studies, including study design, study location, diagnosis, sample size, and age. [Table 2](#t2-rmhp-11-025){ref-type="table"} lists data on visual outcomes for various diagnoses, compliance to glasses and patches, percentage of parents/guardians not able to afford glasses, and parent's education status. Data on effectiveness, cost of glasses, and incremental cost-effectiveness ratio (ICER) are listed in [Table 3](#t3-rmhp-11-025){ref-type="table"}.

Cost data
---------

Percentage difference in the cost of glasses per patient was computed for various diagnosis compared to refractive error. Additionally, percentage difference in the cost of patches per patient was computed for various diagnosis compared to anisometropia. Cost of glasses, contact lenses, and patches were projected over a 5-year time horizon assuming a child of age 4 years is diagnosed and he/she continues to wear glasses, contact lenses, patches, etc., until the age of 9 years.

Effectiveness data
------------------

Effectiveness or quality of life due to amblyopia, high refractive error in non-compliant children, and congenital cataract cases with delayed treatment was obtained from the literature. Additionally, ICER for each diagnosis was computed using formula from the literature[@b11-rmhp-11-025] assuming excellent quality of life (utility equals 1) for healthy patients incurring zero cost.

Results
=======

Study characteristics
---------------------

The characteristics of the studies involved in statistical analysis included datasets from the US,[@b4-rmhp-11-025],[@b12-rmhp-11-025]--[@b16-rmhp-11-025] UK,[@b17-rmhp-11-025] Germany,[@b18-rmhp-11-025] Sweden,[@b19-rmhp-11-025] India,[@b20-rmhp-11-025] People's Republic of China,[@b21-rmhp-11-025] Singapore,[@b22-rmhp-11-025] and Tanzania.[@b23-rmhp-11-025] Further, the study design of the included works examined cost analysis,[@b14-rmhp-11-025],[@b15-rmhp-11-025] cost-effectiveness analysis,[@b16-rmhp-11-025],[@b18-rmhp-11-025]--[@b20-rmhp-11-025] cohort studies,[@b17-rmhp-11-025],[@b21-rmhp-11-025],[@b22-rmhp-11-025] randomized controlled trials,[@b12-rmhp-11-025],[@b23-rmhp-11-025] chart review,[@b13-rmhp-11-025] and a cross-sectional study.[@b4-rmhp-11-025] Diagnosis in the studies included strabismus, amblyopia, anisometropia, esotropia, myopia, congenital cataract, and refractive errors ([Table 1](#t1-rmhp-11-025){ref-type="table"}). Sample size in the included studies ranged from 48 to 6,904 patients.

Annual cost of the glasses per patient in included studies was highest for congenital cataract patients and lowest for refractive error patients. Annual cost of contact lenses per patients was highest for patients with congenital cataract.

Patients with visual acuity of 20/20 varied from 15.5% to 100%, 20/32 varied from 29.3% to 49.4%, 20/40 from 8.8% to 20.3% ([Table 2](#t2-rmhp-11-025){ref-type="table"}). Castanon Holguin et al reported a major problem of compliance to glasses for strabismus patients, which resonates with the literature.[@b24-rmhp-11-025] Li et al[@b21-rmhp-11-025] reported that 40% of refractive error patients were not able to afford glasses. Compliance to patches decreased with duration of treatment.

Cost-effectiveness analysis
---------------------------

[Table 3](#t3-rmhp-11-025){ref-type="table"} lists effectiveness, cost of glasses per patient, and ICER for various diagnoses. For amblyopia patients, cost of glasses per quality-adjusted life years (QALYs) gained was US\$3,638. Cost of glasses for congenital cataract patients with delayed treatment was US\$1,690 per utility gained. Cost of glasses for high refractive error was US\$92.67 per utility gained in non-compliant children.

Cost analysis
-------------

In [Figure 2](#f2-rmhp-11-025){ref-type="fig"}, percentage difference in the annual cost of glasses per patient according to various diagnoses compared to refractive error was computed. Results indicated that the annual cost of glasses for patients with refractive error was 97% less expensive compared to patients with congenital cataract, 94% less expensive compared to amblyopes (mixed), 93% compared to esotropes, 92% compared to patients with strabismus, 89% compared to anisometropes, and 86% compared to myopes.

Percentage difference in the annual cost of patches ([Figure 3](#f3-rmhp-11-025){ref-type="fig"}) per patient according to various diagnoses compared to anisometropia was computed. Results indicated that the annual cost of patches for anisometropes was 92% less expensive compared to patients with congenital cataract, 84% less expensive compared to amblyopes (mixed), and 81% compared to patients with strabismus. This suggests that the annual cost of patches for low-income families with congenital cataract, amblyopia, or strabismus patients may represent a significant financial burden.

The cost of glasses ([Figure 4](#f4-rmhp-11-025){ref-type="fig"}) and patches ([Figure 5](#f5-rmhp-11-025){ref-type="fig"}) was projected over a 5-year time horizon. The cost of glasses increased considerably for congenital cataract patients to US\$18,208 making them unaffordable for economically challenged families over time. On the other hand, annual cost of glasses for refractive error patients increased to US\$55.6 over a 5-year time horizon. For esotropia patients, annual cost of glasses per patient increased to US\$840, for myopes to US\$410.5, for amblyopes (mixed) to US\$915.8, for anisometropes to US\$520.6, and for patients with strabismus to US\$727.6 over a 5-year period. [Figure 5](#f5-rmhp-11-025){ref-type="fig"} shows that the annual cost for patching increased to US\$945, US\$470.45, US\$395.15, and US\$75.9 for patients with congenital cataract, amblyopia (mixed), strabismus, and anisometropia, respectively, over a 5-year time horizon.

Discussion
==========

Our results indicated that for amblyopia patients, cost of glasses per QALYs gained was US\$3,638. Cost of glasses for congenital cataract patients with delayed treatment was \$1,690 per utility gained. Additionally, yearly cost of glasses and patches per patient increased considerably over time for congenital cataract, amblyopia, and strabismus patients. Our results suggest that the annual cost of glasses for pediatric eye patients from low-income families -- if covered or discounted -- may have a long-lasting impact in enhancing patient's health-related quality of life.

A significant strength of our analysis stems from the fact that all the included studies had coherent results of improvement in visual outcomes posttreatment. There was heterogeneity between studies. This degree of heterogeneity could be a consequence of several factors, including consistency in the way the procedures were performed, geographic location, available facilities, follow-up period, rates of compliance, and the year in which the study was conducted. On the other hand, our purpose was to quantitatively assemble the available data on this rather unknown subject. Second, the quality of the included studies was accessed using a Downs and Black checklist,[@b10-rmhp-11-025] and we did find high-, medium-, and poor-quality studies. However, we included all studies, irrespective of their quality, because of the limited number of articles we encountered on this topic. We found limited information on preoperative and postoperative contrast sensitivity, stereopsis, and astigmatism to conduct our quantitative analysis, and thus these characteristics were excluded from the analysis. It was also not the purpose of the study. Third, cost-utility analysis of observational studies is influenced by inherent bias in the included articles.[@b25-rmhp-11-025] For example, a multitude of other factors -- income status, socioeconomic status, previous ocular and non-ocular surgeries, family history, other ocular and non-ocular diseases, preoperative and postoperative medications, number of medications -- can influence the estimates in the original studies. Fourth, many studies had to be excluded due to lack of necessary information. Fifth, only studies published in English were included. If all the excluded studies had been considered, such an inclusion would unlikely make a considerable impact since our cost-utility analysis agreed with published studies.

In sum, our results showed that there is considerable cost to patient per health utility gained and annual cost of glasses per patient increased considerably. Thus, patients may use less costly frames instead of buying expensive trendy frames to help mitigate the cost.[@b26-rmhp-11-025] If a child's prescription changes often, then new lenses in the old frame may help save some money.[@b27-rmhp-11-025] Further, other means of reducing cost such as covering for the first pair of glasses, educating parents about substantial visual deficits of not wearing glasses, or providing glasses at a discounted price for low-income families should be considered by health care planning authorities in governments all over the world.

Supplementary material
======================

###### 

Screening questions
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###### 

Baseline characteristics of included studies

  Study                                     Study design            Study location               Diagnosis                                      Sample size   Age (years)   
  ----------------------------------------- ----------------------- ---------------------------- ---------------------------------------------- ------------- ------------- -------
  Awan et al[@b17-rmhp-11-025]              Cohort study            UK                           Strabismus, (mixed) amblyopia, anisometropia   321           4.1           1.73
  Carrigan et al[@b12-rmhp-11-025]          RCT                     USA                          Aphakia post-congenital cataract removal       114           0.292         0.104
  Costello et al[@b13-rmhp-11-025]          Chart review            USA                          Esotropia                                      48            3.8           1.5
  Frick et al[@b20-rmhp-11-025]             CE analysis             India                        Refractive error                               --            11            2
  Ghasia and Tychsen[@b16-rmhp-11-025]      CE analysis             USA                          Refractive error                               87            10.1          4.56
  König and Barry[@b18-rmhp-11-025]         CE analysis             Germany                      Amblyopia                                      --            3             --
  Kruger et al[@b15-rmhp-11-025]            Cost analysis           USA                          Congenital cataract                            114           0.25          1.5
  Li et al[@b21-rmhp-11-025]                Cohort study            People's Republic of China   Refractive error                               597           14.7          0.8
  Lim et al[@b22-rmhp-11-025]               Cohort study            Singapore                    Myopia                                         301           14.5          1.25
  Magnusson and Persson[@b19-rmhp-11-025]   CE analysis             Sweden                       Congenital cataract                            --            --            --
  Stager et al[@b14-rmhp-11-025]            Cost analysis           USA                          Congenital cataract                            --            --            --
  Wedner et al[@b23-rmhp-11-025]            RCT                     Tanzania                     Refractive error                               6,904         14.4          1.75
  Zhang et al[@b4-rmhp-11-025]              Cross-sectional study   USA                          Refractive error                               1,794         10.5          0.5

**Abbreviations:** RCT, randomized clinical trial; CE analysis, cost-effectiveness analysis.

###### 

Visual outcome and compliance reported in included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                              Diagnosis              Visual outcome (% of children)   Compliance to glasses                                                                                                 Compliance to patches                                                                                                                                                                    Glasses not affordable (%)
  ---------------------------------- ---------------------- -------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  Awan et al[@b17-rmhp-11-025]       Strabismus             20/20 (18.9); 20/32\             Major problem                                                                                                         Compliance decreased with treatment duration                                                                                                                                             --
                                                            (63.5); 20/40 (83.8)                                                                                                                                                                                                                                                                                                                            

  (Mixed) amblyopia                  20/20 (15.5); 20/32\   --                               Compliance decreased with treatment duration                                                                          --                                                                                                                                                                                       
                                     (44.8); 20/40 (63.8)                                                                                                                                                                                                                                                                                                                                                   

  Anisometropia                      20/20 (18.7); 20/32\   --                               Compliance decreased with treatment duration                                                                          --                                                                                                                                                                                       
                                     (68.1); 20/40 (76.9)                                                                                                                                                                                                                                                                                                                                                   

  Costello et al[@b13-rmhp-11-025]   Esotropia              --                               2% wore glasses \<10% of the time; 14% wore glasses \>50% but \<90% of the time; 82% wore glasses \>90% of the time   12% wore patch or used occluding drops \<10% of the time; 12% wore patch or used occluding drops \>50% but \<90% of the time; 76% wore patch or used occluding drops \>90% of the time   --

  Li et al[@b21-rmhp-11-025]         Refractive error       20/20 (100)                      Usually (26%); sometimes (63%); seldom (11%)                                                                          --                                                                                                                                                                                       40

  Wedner et al[@b23-rmhp-11-025]     Refractive error       --                               Free spectacles compliance (82%); prescription only compliance (30%)                                                  --                                                                                                                                                                                       13.7
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Dashes indicate that data was not available.

###### 

Effectiveness due to amblyopia, refractive error, and congenital cataract

  Study                                     Diagnosis                                                    Effectiveness data   Unit of effectiveness   Cost of glasses (US\$/patient)   ICER
  ----------------------------------------- ------------------------------------------------------------ -------------------- ----------------------- -------------------------------- -------
  Ghasia and Tychsen[@b16-rmhp-11-025]      High RE (non-compliant children)                             0.88                 Utility                 11.12                            92.67
  König and Barry[@b18-rmhp-11-025]         Amblyopia (mixed)                                            0.96                 QALYs                   145.52                           3638
  Magnusson and Persson[@b19-rmhp-11-025]   Congenital cataract with IOL, cases with delayed treatment   0.8                  Utility                 338                              1690

**Abbreviations:** ICER, incremental cost-effectiveness ratio; RE, refractive error; QALYs, quality-adjusted life years; IOL, intraocular lens.
